GNH USA

Europe — EMA

Moxonidina Eg (Moxonidine)

GNH USA supplies Moxonidina Eg (Moxonidine), a Imidazoline I1 receptor agonist for hypertension. Request a quote for global supply, available worldwide.

Moxonidine

Request sourcing

1
Pack/s

What is Moxonidine?

Moxonidine, the active ingredient in Moxonidina Eg, is an Imidazoline I1 receptor agonist presented as an oral tablet for systemic use. It is employed to lower elevated blood pressure in adults with hypertension, acting on central sympathetic pathways to achieve blood pressure control. It is indicated for essential hypertension and may be used as adjunct therapy in resistant cases.

GNH USA supplies Moxonidina Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

What is Moxonidine used for?

Moxonidine is used to treat hypertension by modulating central sympathetic activity.

- Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary high blood pressure. - Secondary hypertension: may be added when blood pressure elevation is due to identifiable causes and other agents are insufficient. - Resistant hypertension: used as adjunct therapy when target pressure is not achieved with standard antihypertensives.

What are the side effects of Moxonidine?

Moxonidine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: sensation of oral dryness. - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headedness, especially when standing quickly. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: unusually slow heart rate. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Liver enzyme elevation: abnormal liver function tests indicating possible hepatic involvement.

What precautions apply to Moxonidine?

Before initiating therapy, consider the following safety measures.

- Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: unknown excretion; use with caution. - Renal impairment: dose may need adjustment; monitor renal function. - Hepatic impairment: use cautiously; monitor liver enzymes. - Concomitant antihypertensives: risk of additive blood‑pressure lowering effects. - Elderly patients: may be more sensitive to hypotensive effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

What does Moxonidine interact with?

Moxonidine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Combined use with other central antihypertensives (e.g., clonidine) may cause excessive hypotension. - Co‑administration with strong CYP2D6 inhibitors may increase plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood‑pressure lowering effect. - Beta‑blockers: additive effect on heart rate and blood pressure. - ACE inhibitors or ARBs: monitor for synergistic hypotensive response.

Frequently asked questions

What is Moxonidina Eg used for?+
Moxonidina Eg contains the active ingredient moxonidine and is used to treat hypertension. By targeting central sympathetic pathways, it helps lower elevated blood pressure in adults diagnosed with essential or resistant hypertension.
How does moxonidine work?+
Moxonidine acts as a selective agonist at imidazoline I1 receptors in the brainstem. Activation of these receptors reduces sympathetic nervous system activity, leading to decreased peripheral vascular resistance and a modest reduction in arterial blood pressure.
What is the usual dose of Moxonidina Eg?+
The appropriate dose of Moxonidina Eg is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments are made according to clinical judgment.
Is Moxonidina Eg safe during pregnancy or breastfeeding?+
Safety of moxonidine in pregnancy has not been established, and it is generally avoided unless the potential benefit justifies the risk. Information on excretion in breast milk is limited, so use while breastfeeding should be considered only if clearly needed.
How do I order Moxonidina Eg from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com with the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does moxonidine compare with other antihypertensive classes?+
Moxonidine belongs to the imidazoline I1 receptor agonist class, offering a modest blood‑pressure reduction with a lower incidence of reflex tachycardia compared with some centrally acting agents like clonidine. It is often used when patients need an additional agent beyond ACE inhibitors, ARBs, diuretics or calcium‑channel blockers.
What are the storage and handling requirements for Moxonidina Eg?+
Moxonidina Eg should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture and direct sunlight to maintain stability throughout its shelf life.
How is Moxonidina Eg administered?+
Moxonidina Eg is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.
What are the most serious risks associated with Moxonidina Eg?+
Serious adverse events, although rare, include severe hypotension, bradycardia, allergic reactions such as rash or anaphylaxis, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience symptoms like fainting, rapid heartbeat, or signs of an allergic reaction.
Who should not use Moxonidina Eg?+
Moxonidina Eg is contraindicated in patients with known hypersensitivity to moxonidine or any excipients in the formulation. It should be used with caution, or avoided, in individuals with severe renal or hepatic impairment, uncontrolled heart failure, or those who are pregnant unless the benefit outweighs the risk.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Moxonidine
Route
Oral Use
Manufacturer
Eg S.P.A.
Origin
EU

Related products

Cynt

Cynt

Moxonidine

Viatris Hrvatska D.O.O.
EU
Cynt

Cynt

Moxonidine

Viatris Healthcare Limited
EU
Cynt

Cynt

Moxonidine

Viatris Healthcare Limited
EU
Cynt

Cynt

Moxonidine

Biomin, A.S.
EU